Skip to main content
See every side of every news story
Published • loading... • Updated

Wells Fargo & Company Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)

Summary by MarketBeat
Wells Fargo & Company started coverage on shares of Supernus Pharmaceuticals in a research note on Friday. They issued an "overweight" rating and a $54.00 price objective on the stock.

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Friday, November 20, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal